GLP 1

Most people seeking weight loss medication have a long diet history.

Generally, no. Pre-existing gastroparesis is listed as a relative contraindication on the Ozempic, Wegovy, Mounjaro, and Zepbound FDA labels.

Chronic stress is a measurable metabolic problem, not just a quality of life issue.

Emotional eating affects an estimated 40% of U.S. adults, with higher rates in adults with obesity, depression, and anxiety.

The intersection of prior eating disorder history and GLP-1 weight loss medications requires careful evaluation.

People living with disabilities often face higher rates of obesity and obesity-related conditions.

Yes, sometimes. GLP-1 medications slow gastric emptying, which can affect dental procedures and surgery that involve anesthesia or sedation.

Twice a year, most of the United States shifts the clock by one hour.

Crohn’s disease is not an absolute contraindication for GLP-1 receptor agonists, but it complicates the picture.